Which type of EGFR mutated lung cancer patients is more suitable for lazertinib?

Lazertinib (Lazertinib) is a third-generation oral small molecule tyrosine kinase inhibitor (TKI) targeting EGFR mutations, specifically designed to treat carriers n>EGFRNon-small cell lung cancer (NSCLC) patients with sensitive mutations, especially those who are resistant to first- or second-generation EGFR inhibitors. It is highly targeted and can effectively suppress common sensitive mutations such as 19 exon deletion (Exon 19 deletion) and L858R point mutations in exon 21, and also has significant activity against the T790M resistance mutation that is difficult to control with second-generation EGFR inhibitors.

For patients with advanced non-small cell lung cancer who are first diagnosed with EGFR sensitive mutations, lanzetinib has shown good efficacy and safety and can be used as a first-line treatment option. Its high selectivity and good blood-brain barrier penetration make it particularly effective in the prevention and treatment of patients with brain metastases, which has important clinical significance for patients with EGFR mutated lung cancer who are at a higher risk of brain metastases.

In addition, Lanzertinib is also suitable for patients with T790M mutation detected after failure of first- or second-generation EGFR-TKI treatment. The drug can overcome T790M mediated drug resistance, delay disease progression and improve patient survival. Compared with other third-generation EGFR inhibitors, lanzetinib also has certain advantages in controlling side effects and improving patients' quality of life.

In short, lanzertinib is more suitable for patients with non-small cell lung cancer who carry EGFR sensitive mutations and may be combined with T790M resistant mutations, especially those with brain metastases. Doctors usually choose lanzitinib as the first or subsequent treatment option based on the patient's mutation type, disease progression, and previous treatment history to obtain the best treatment effect.

Reference materials:https://www.drugs.com/